San Diego, Calif., December 9, 2016 – Forge Therapeutics, Inc. today announced a strategic alliance with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, [...]
Startup Spotlight: Forge Therapeutics Armed with a novel chemistry platform from the UC San Diego lab of Professor Seth Cohen and Dr. David [...]
San Diego, Calif., September 12, 2016 – Forge Therapeutics, Inc. announced the additions of Dr. Brad Spellberg, M.D., Chief Medical Officer of Los [...]
San Diego, Calif., September 7, 2016 – Forge Therapeutics, Inc., announced presentations on its lead program targeting LpxC with novel chemistry to combat [...]
San Diego, Calif., August 16, 2016 – Forge Therapeutics, Inc. announced today Dr. Seth Cohen, Ph.D., co-founder of Forge Therapeutics and Professor in [...]
World-renowned antibiotic experts form Key Opinion Team to advise Forge San Diego, Calif., July 26, 2016 – Forge Therapeutics, Inc. today announced its 1st [...]
http://timesofsandiego.com/business/2016/07/05/five-questions-san-diego-startup-forge-therapeutics/
First ever non-hydroxamate inhibitor of LpxC to demonstrate efficacy in preclinical models of Gram-negative bacteria infection San Diego, Calif., June 14, 2016 – Forge [...]
San Diego, Calif., June 1, 2016 – Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting [...]
Cool Company: San Diego Venture Group has selected Forge Therapeutics a ‘2016 Cool Company’ and only 20 start-up companies across all technology areas [...]
